Heading Into Earnings, Expectations Are Rising For These 4 Biotech Stocks
Heading into an earnings season in which many companies will be posting much lower earnings as a result of the pandemic.
Heading into an earnings season in which many companies will be posting much lower earnings as a result of the pandemic.
A trio of biotech firms IPOed on Friday – and saw double-digit gains on their trading debuts.
A look at the four biotech companies going public Friday – which include two firms developing small molecule therapies to treat cancer.
“The health care sector, some biotech stocks in particular, are looking to explode in 2021,” declares the author of today’s article, who further notes that “There have been some breakout companies as a result of the coronavirus pandemic, but other catalysts will be playing into the expected gains as well.”
The four penny stocks highlighted in today’s article are all biopharmaceutical/biotech companies, they can all be bought for under $4, and they all have important upcoming events.
“September has historically been the worst-performing month for stocks – and today’s article identifies the stocks that have shown themselves to be the worst stocks to own in September over the past 10 years.
Four biotech penny stocks to consider for your watch list right now.